Related Experiment Video
Updated: Mar 24, 2026

Modified Octopus Technique for Thoracoabdominal Aortic Aneurysm
Published on: August 1, 2025
Efficacy and Safety of Endovascular Therapy for Aortoiliac TASC D Lesions
Kenji Suzuki1, Yukiko Mizutani2, Yoshimitsu Soga3
1Department of cardiology, Saiseikai Central Hospital, Minato-ku, Tokyo, Japan k-y.suzuki@nifty.com.
Insights
Endovascular therapy for complex aortoiliac occlusive disease, including TASC D lesions, shows lower procedural success but similar long-term patency and major adverse events compared to TASC A-C lesions.
Area of Science:
- Vascular Surgery
- Endovascular Interventions
- Peripheral Artery Disease
Background:
- Endovascular therapy is increasingly effective for aortoiliac (AI) occlusive disease.
- Application to TASC D lesions remains less understood and applied.
Purpose of the Study:
- To compare outcomes of endovascular therapy for TASC D aortoiliac lesions versus TASC A-C lesions.
- To identify predictors of major adverse cardiovascular and limb events (MACLE) in TASC D patients.
Main Methods:
- Retrospective analysis of 2096 patients (2601 limbs) with AI occlusive disease.
- Lesions categorized as TASC D (395) or TASC A-C (2206).
- Comparison of baseline data, procedural success, complications, and 5-year follow-up results.
Main Results:
- Lower procedural success (91.6% vs 99.3%) and higher complication rates (11.1% vs 5.2%) in the TASC D group.
- No significant difference in 5-year primary patency (77.9% vs 77.1%) or MACLE (30.5% vs 33.4%) between groups.
- Complications and critical limb ischemia independently predicted MACLE in TASC D patients.
Conclusions:
- Endovascular therapy for TASC D AI lesions has lower procedural success and higher complication rates.
- Despite initial challenges, long-term outcomes regarding patency and MACLE are comparable to less complex lesions.
- Managing complications is crucial for improving MACLE outcomes in TASC D patients.
Background:
Although there is increasing evidence of the effectiveness of endovascular therapy for complex aortoiliac (AI) occlusive disease, it is not universally applied to TASC D lesions.
Methods:
A total of 2096 patients, 2601 limbs with AI occlusive disease, were enrolled. The lesions were categorized as TASC D (395) or TASC A-C (2206), and we compared baseline data, procedure, and follow-up result between the 2 groups.
Results:
The success rate of the procedure was significantly lower in the TASC D group (91.6% vs 99.3%, P < .01), and more procedure complications occurred in the TASC D group (11.1% vs 5.2%, P < .01). The results of a 5-year follow-up revealed no significant difference in primary patency (77.9% vs 77.1%, P = .17) and major adverse cardiovascular and limb events (MACLE; 30.5% vs 33.4%, P = .42) between the 2 groups. A multivariate analysis revealed complications and critical limb ischemia are independent predictors of MACLE in the TASC D group.
Conclusion:
The success rate of the procedure was lower in the TASC D group. Complications were more frequent in the TASC D group, and they were related to MACLE.
Related Concept Videos
Aneurysm III: Interprofessional Care
Venous Thrombosis III: Interprofessional Care
